Dr. William Williams reports

BRIACELL REPORTS 71% CENTRAL NERVOUS SYSTEM RESPONSE RATE IN ADVANCED BREAST CANCER PATIENTS

Briacell Therapeutics Corp. has observed a marked 71-per-cent intracranial objective response rate (iORR) in advanced breast cancer patients suffering from central nervous system (CNS) metastases and treated with Briacell's Bria-IMT regimen. iORR is defined as the percentage of patients who achieve either a complete response (complete disappearance) or partial response (volume reduction of 30 per cent or more) in intracranial tumours.

Breast cancer metastasis (spread of the cancer) to the CNS presents a significant clinical challenge, often leading to poor prognosis and early death. Briacell has recently conducted a retrospective analysis in breast cancer patients with CNS metastases enrolled across both its Bria-IMT monotherapy and combination therapy with CPI studies and found remarkable clinical responses.

"We have accumulated positive clinical responses in five patients with intracranial metastases, which generally are extremely difficult to treat, and have a very poor prognosis. This anti-tumour activity furthers our excitement in our ongoing phase 3 pivotal trial studying the Bria-IMT regimen in advanced breast cancer," stated Dr. William V. Williams, Briacell's president and chief executive officer.

"The CNS tumour reductions demonstrated in five of seven advanced breast cancer patients are particularly compelling given the history of unsuccessful treatment of CNS metastases in this patient population," stated Dr. Giuseppe Del Priore, Briacell's chief medical officer.

Briacell clinical data in advanced metastatic breast cancer patients with CNS metastases.

The Bria-IMT regimen (alone or combined with a CPI):

• CNS lesions improved in 71 per cent of patients (five of seven), supporting clinical efficacy of the Bria-IMT regimen. Findings provide evidence for the efficacy of the Bria-IMT regimen, both alone and in combination with CPI, in CNS metastases patients.

• Heavily pretreated metastatic breast cancer patients had failed multiple prior treatments including one patient who had failed treatments with two antibody-drug conjugates.

• Regression of CNS metastatic tumours was observed across all breast cancer subtypes in heavily pretreated patients highlighting the potential of the Bria-IMT regimen in managing CNS metastases

Briacell is adding a preplanned subgroup analysis of patients with CNS metastases to its pivotal phase 3 study in advanced metastatic breast cancer patients. This could provide an additional indication for market approval of Bria-IMT.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.